A

Aclaris Therapeutics
D

ACRS

2.58500
USD
0.00
(0.00%)
مغلق
حجم التداول
20,586
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
276,643,430
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADCT
    -0.06000
    (-3.40%)
    1.70500 USD
    A
    AGEN
    -0.15000
    (-3.94%)
    3.66000 USD
    A
    ALXO
    0.15000
    (9.15%)
    1.79000 USD
    AMGN
    AMGN
    -1.26
    (-0.46%)
    273.59 USD
    A
    ASMB
    0.282
    (1.97%)
    14.610 USD
    B
    BCRX
    0.01500
    (0.20%)
    7.62000 USD
    BIIB
    BIIB
    1.810
    (1.28%)
    142.750 USD
    B
    BPMC
    -0.940
    (-0.84%)
    111.190 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    I
    INCY
    -1.050
    (-1.43%)
    72.420 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    N
    NKTR
    0.02170
    (2.39%)
    0.93110 USD
    NVS
    NVS
    -1.600
    (-1.60%)
    98.180 USD
    P
    PTCT
    -0.150
    (-0.33%)
    45.100 USD
    المزيد
الأخبار
المقالات

العنوان: Aclaris Therapeutics

القطاع: Healthcare
الصناعة: Diagnostics & Research
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; andATI-1777.